Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Information Forecast till 2023

$4,450$6,250

Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Information By Treatment (Intravenous Immunoglobulin, Corticosteroids, Plasmapheresis (Plasma Exchange), Physiotherapy, Others), Diagnosis (Electrodiagnostic Testing, Nerve Conduction, EMG, Spinal Fluid Analysis, Others), By Route of Administration (Intravenous, Oral, Others), By End User (Hospitals, Specialty Neurological Clinics, Research & Academic Laboratories, Others) and Top Regions Forecast till 2023

Clear

Description

 

Market analysis

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an uncommon neurological immune system issue where myelin, a fundamental part of the nervous system is being attacked by the immune system of the body. There has been a spiraling ascent in the predominance of autoimmune disorders in the past which offers scope for the development of the global chronic inflammatory demyelinating polyneuropathy disease market. Different new medications have been propelled into the market after ongoing FDA endorsements which likewise supports the development of the global chronic inflammatory demyelinating polyneuropathy disease market. Different factors empowering the development of the market incorporate growing awareness about the disease and government attempts in the same issue. On the drawback, the mind-boggling expense of Intravenous immunoglobulin treatment and its side effects remains the major obstruction to the development of the market. The market is growing at a CAGR of 6.2% and is anticipated to reach USD 3907.17 Mn by the end of the forecast period 2018-2023.

Market segmentation

Based on its treatment & diagnosis, the global chronic inflammatory demyelinating polyneuropathy disease market is segmented as Corticosteroids, Treatment Intravenous Immunoglobulin, Electrodiagnostic Testing, Physiotherapy, Spinal Fluid Analysis, Nerve Conduction, Plasmapheresis (plasma exchange), Diagnosis, EMG, Others. By end-user, the market is segmented as Specialty Neurological Clinics, Hospitals, Research & Academic Laboratories, Others. By route of administration, the market is again bifurcated into oral, intravenous and others.

Regional analysis

Geographically, the global chronic inflammatory demyelinating polyneuropathy disease market is divided into global regions like Europe, North America, Asia- Pacific, Middle East, LATAM, and Africa.

Major players

Kedrion S.p.A, Octapharma, Shire, Mitsubishi Tanabe Pharma Corporation, Momenta Pharmaceuticals, Grifols, Baxter, among others are some of the major players in the global chronic inflammatory demyelinating polyneuropathy disease market.

Table of Contents

Table of Contents:

1 Report Prologue
2 Executive Summary
3 Market Introduction
3.1 Definition
3.2 Scope of the Study
3.3 Research Objective
3.4 Assumptions & Limitations
3.4.1 Assumptions
3.4.2 Limitations
3.5 Market Structure
4 Research Methodology
4.1 Research Process
4.2 Primary Research
4.3 Secondary Research
4.4 Market Size Estimation
4.5 Forecast Model
5 Market Dynamics
5.1 Introduction
5.2 Drivers
5.2.1 Rising prevalence of autoimmune diseases
5.2.2 Increasing research and development related to plasma-derived medicines
5.2.3 Increasing awareness about Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
5.3 Restraints
5.3.1 Side-effects associated with the Intravenous Immunoglobulin (IVIG) treatment
5.3.2 High cost of the IVIG treatment
5.4 Opportunity
5.4.1 Advancements in the treatment
5.5 Clinical Trials Data
6 Market Factor Analysis
6.1 Porter’s Five Forces Model
6.1.1 Bargaining Power of Suppliers
6.1.2 Bargaining Power of Buyers
6.1.3 Threat of New Entrants
6.1.4 Threat of Substitutes
6.1.5 Intense Rivalry
6.2 Supply Chain Analysis
6.2.1 R&D and Designing
6.2.2 Manufacturing
6.2.3 Distribution & Sales
6.2.4 Post-Sales Monitoring
7 Global Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis
7.1 Introduction
7.2 Treatment
7.3 Diagnosis
8 Global Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration
8.1 Introduction
8.2 Intravenous
8.3 Oral
9 Global Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User
9.1 Introduction
9.2 Hospitals
9.3 Specialty Neurological Clinics
9.4 Research & Academic Laboratories
10 Global Chronic Inflammatory Demyelinating Polyneuropathy Market, By Region
10.1 Introduction
10.2 Americas
10.2.1 North America
10.2.1.1 U.S.
10.2.1.2 Canada
10.2.2 South America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 U.K
10.3.1.4 Italy
10.3.1.5 Spain
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 Republic of Korea
10.4.6 Rest of Asia Pacific
10.5 Middle East and Africa
10.5.1 Middle East
10.5.2 Africa
11 Competitive Landscape
11.1 Company Market Share Analysis
11.2 Introduction
12 Company Profiles
12.1 Grifols
12.1.1 Company Overview
12.1.2 Financial Overview
12.1.3 Products/Services Offered
12.1.4 SWOT Analysis
12.1.5 Key Developments
12.1.6 Key strategy
12.2 Shire
12.2.1 Company Overview
12.2.2 Financial Overview
12.2.3 Products/Services Offered
12.2.4 SWOT Analysis
12.2.5 Key Developments
12.2.6 Key strategy
12.3 Baxter
12.3.1 Company Overview
12.3.2 Company Overview
12.3.3 Products/Services Offered
12.3.4 SWOT Analysis
12.3.5 Key Developments
12.3.6 Key strategy
12.4 Pfizer, Inc.
12.4.1 Company Overview
12.4.2 Financial Overview
12.4.3 Products/Services Offered
12.4.4 SWOT Analysis
12.4.5 Key Developments
12.4.6 Key Strategy
12.5 CSL Behring
12.5.1 Company Overview
12.5.2 Financial Overview
12.5.3 Products/Services Offered
12.5.4 SWOT Analysis
12.5.5 Key Developments
12.5.6 Key Strategy
12.6 Kedrion S.p.A
12.6.1 Company Overview
12.6.2 Financial Overview
12.6.3 Products/Services Offered
12.6.4 SWOT Analysis
12.6.5 Key Development
12.6.6 Key Strategy
12.7 Octapharma
12.7.1 Company Overview
12.7.2 Financial Overview
12.7.3 Products/Services Offered
12.7.4 SWOT Analysis
12.7.5 Key Development
12.7.6 Key Strategy
12.8 Momenta Pharmaceuticals
12.8.1 Company Overview
12.8.2 Financial Overview
12.8.3 Products/Services Offered
12.8.4 SWOT Analysis
12.8.5 Key Development
12.8.6 Key Strategy
12.9 Teijin Pharma Limited
12.9.1 Company Overview
12.9.2 Financial Overview
12.9.3 Products/Services Offered
12.9.4 SWOT Analysis
12.9.5 Key Developments
12.9.6 Key strategy
12.1 Mitsubishi Tanabe Pharma Corporation
12.10.1 Company Overview
12.10.2 Financial Overview
12.10.3 Products/Services Offered
12.10.4 SWOT Analysis
12.10.5 Key Developments
12.11 Bio Products Laboratory Ltd.
12.11.1 Company Overview
12.11.2 Financial Overview
12.11.3 Products/Services Offered
12.11.4 SWOT Analysis
12.11.5 Key Developments
12.11.6 Key strategy
13 Appendix
13.1 Discussion Blue Print

Additional information

Publisher

Geography Covered

Date Published

Pages

Format